Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PCNA”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 181 records · Page 10Linked to original sources

[Proliferating cell nuclear antigen (PCNA) in ovarian carcinoma and its relation to lymph node metastasis and prognosis].

OBJECTIVE: To investigate expression of proliferating cell nuclear antigen (PCNA) in ovarian epithelial cancer and its relation to lymph node metastasis, second-look laparotomy (SLL) and prognosis. METHODS: Monoclonal antibody PC10 was used to stain PCNA in archival paraffin-embedded tissues. RESULTS: PC10 immunostaining was performed successfully in all 74 primary and 31 intraperitoneal metastatic tumors. The expression of PCNA was significantly elevated in 31 metastatic tumors compared with their primary tumor from the same patient (7.94 vs 6.89, P = 0.042). The expression was more marked in bilateral than in unilateral ovarian cancer but it was not associated with lymph node metastasis, clinical stage, histologic grade and subtype. In 28 patients with stage III ovarian cancer undergone SLL, the mean immunoreactive score (IRS) of PCNA of the primary tumor was significantly higher in patients with negative SLL than in those with positive SLL (7.59 vs 6.10, P = 0.03). Since chemotherapy was performed following surgical debulking, negative SLL more frequently seen in patients with high PCNA expression might suggest better chemotherapeutic sensitivity due to higher proliferation fraction of tumor cells. Univariate analysis of survival indicated that the overall survival was inversely associated with the level of PCNA expression, while multivariate analysis with Cox's model showed that independent prognostic factors were the residual tumor after primary debulking (P < 0.001) and clinical stage (P < 0.05), followed by PCNA expression (P = 0.09). CONCLUSION: The expression of PCNA may be useful in predicting prognosis, but is not correlated with lymph node metastasis.

Adult↗

C-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer.

This study was designed to evaluate the prognostic importance of c-erbB-2 and proliferating cell nuclear antigen (PCNA) with long-term follow-up in Japanese patients with breast cancer. Four hundred and eight patients with breast cancer were studied. We investigated 6 factors, including c-erbB-2, PCNA, lymph-node status (n), clinical tumor size (T), histological grade (HG) and lymphatic vessel invasion, followed for a median of 10 years. c-erbB-2 overexpression was found in 35.0% and PCNA in 43.1% of the carcinomas. c-erbB-2 positivity was correlated with PCNA (p < 0.0001), n (p<0.0001), T (p = 0.0016), and HG (p = 0.0110). Univariate analysis showed that c-erbB-2 was significantly predictive of 20-year overall survival (OS) (p = 0.0247), but not of 20-year relapse-free survival (RFS). PCNA was significantly associated with 20-year RFS and OS (p <0.0001, p < 0.0001, respectively). Multivariate analysis showed that PCNA was an independent prognostic factor in node-negative patients, but c-erbB-2 and PCNA were not independent prognostic indicators in all patients. Although c-erbB-2 expression and PCNA were obviously important from a biological standpoint, they were not recognized as independent molecular markers.

Adolescent↗

[A study of DNA ploidy pattern, proliferation index and PCNA in duodenal carcinoma].

12 cases of duodenal carcinoma were studied for nuclear DNA ploidy patterns, the proliferation index (PI), proliferating cell nuclear antigen (PCNA) positive score (1 = 0-25%, 2 = 26-50%, 3 = 51-75%, 4 = 76-100%) and PCNA positive rate. DNA aneuploidy was observed in 9 cases (75%) and PCNA staining was positive in 11 cases (91.6%). DNA ploidy patterns, PI, PCNA positive scores and positive rates were not related to each other. No relationship DNA ploidy patterns for PCNA positive scores and PCNA positive rates could be found. The relationship between PI and PCNA positive score was found not to be significant (P less than 0.10). PI was revealed to correlate significantly (P less than 0.05) to PCNA positive rate.

Aneuploidy↗

Proliferating cell nuclear antigen (PCNA) expression in childhood lymphomas.

Paraffin sections from 21 cases of Hodgkin's disease (HD) and 28 cases (26 high-grade and 2 low-grade) of non-Hodgkin's lymphomas (NHL) occurring in childhood were examined for the presence of proliferating cell nuclear antigen using an anti-PCNA antibody. All cases of HD and NHL showed PCNA reactivity. In HD 50.9% (mean value) of Hodgkin and Reed-Sternberg (HRS) cells were PCNA positive and judged to be proliferating. PCNA reactivity was also found in a varying number of cells of the background population in HD (mean value = 11.7%). In NHL 61.2% (mean value) of cells were PCNA positive. In the 26 high grade tumours 63.6% (mean value) of cells were PCNA positive while only 32% (mean value) of cells were PCNA positive in the 2 low-grade tumours. Our results show that the proliferation rate of tumour cells in high-grade NHL is higher than those of tumour cells in low-grade NHL and HRS cells in HD. Moreover, we found a considerable variation of proliferation rate among individual cases of HD (range 31%-68%) of NHL (range 31%-78%). This suggests that PCNA assessment can help in the individual approach of the proliferation rate of each tumour, and, in conjunction with other parameters of the cell proliferation, could be useful for the understanding of the biological behavior of childhood lymphomas.

Adolescent↗

[CD69 and PCNA expression of T-lymphocytes from children with cow's milk allergy (CMA)].

BACKGROUND: As the frequency of allergic disease and especially the food allergy in children is still increasing - we undertook studies to determine the specific sensitivity of lymphocytes T in order to improve the diagnostics and monitoring of treatment. The usefulness of evaluation CD69 and PCNA expression of T cells from children with cow's milk allergy (CMA) in these procedures was examined. AIM: The study on usefulness of lymphocytes CD69 and PCNA detection for diagnosis of CMA in children and for monitoring of the treatment. PATIENTS AND METHODS: The subjects in this study included 26 children from 1.5 to 15 years old with CMA who were under clinical care of our Immunological Department. Patients were examined (medical history of the child, physical examination, specific food provocation) and laboratory investigations were made before therapy and after 6 months of elimination diet. Allergen-specific IgE antibody was determined. Children's T cell cultures were stimulated by beta-lactoglobulin, alpha-casein, whole cow's milk, phytohaemoglutinin PHA and without stimulation. Expression of T cells CD69 and PCNA from patients with CMA and 10 healthy children were analysed by use of flow cytometry. 10 children with CMA after 6 months of elimination diet and next 2 weeks with cow's milk provocation were examined also for CD69 and PCNA expression in lymphocytes from peripheral blood. RESULTS: After 6 months of elimination diet it seems that the expression of CD69 receptor has tendency to fall, these differences, however, are not statistically significant. But after next 2 weeks with cow's milk diet the expression of CD69 was increased with statistically significance (p=0.04). T cells PCNA expression of children with CMA was lower than in healthy children in PHA stimulated cultures. Our study indicates that PCNA expression of T cells from patients with CMA increased even more after 6 months of elimination diet in all cultures but there was statistically significant differences only after stimulation with cow's milk and PHA (p=0.05 and p=0.04 - respectively). Subsequently through 2 weeks children were provoked with cow's milk and after that PCNA expression in vivo lowered (no statistically significant differences). CONCLUSIONS: CD69 expression of T lymphocytes was significantly higher after specific stimulation of children with cow's milk allergy (p=0.04). The evaluation of CD69 expression of children with CMA may be also useful in monitoring of treatment. Estimation of PCNA expression suggests the efficiency of T cells connected with DNA synthesis related to the stage of allergy disease and demands further investigations.

Adolescent↗

[Human papillomavirus type 16 E6 oncogene and expression of P53, RB and PCNA in human cervical carcinoma].

The aim of this study was to get some insights into the relationship between human papillomavirus type 16 E6 transforming gene and the expressed products of tumor suppressor gene, the P53, RB and proliferation cell nuclear antigen (PCNA) in human cervical carcinoma. 44 formalin-fixed paraffin-embedded cervical carcinoma sections were screened for P53, RB and PCNA by immunohistochemical assay with their monoclonal antibodies, and for the presence of HPV16 E6 ORF by in situ hybridization with HPV16 E6 DNA probe we have successfully labeled. The presence of HPV16 E6 gene was detected in 27 of 44 specimens (61.3%), including 8 of P53 protein positive (29.63%), 14 of RB protein positive (52.85%), and 20 of PCNA positive (74.07%). Of 17 HPV16 E6 negative cases, there were 7 of P53 protein positive (41.17%), 9 of RB protein positive (52.94%), 12 of PCNA positive (70.58%). There were no HPV16 E6 gene in control group. In positive cases PCNA only expressed in base cells. Our date indicated that HPV16 E6 ORF and PCNA had significantly related to cervical carcinoma. We could not find the relationship between HPV16 E6 ORF and P53, RB, PCNA in cervical carcinoma. There were some HPV16 E6-positive cases, obviously with strong P53, RB immunostaining in cytoplasm but not in nuclei, PCNA immunostaining was strong at the edge of the cervical carcinoma cells than in nuclear of them.

Carcinoma↗

Galectin-3 and proliferating cell nuclear antigen (PCNA) expression in papillary thyroid carcinoma.

BACKGROUND AND AIM: To examine the relationship between galectin-3 and cell proliferation in thyroid tumor tissue. Galectin-3, a beta-galactoside binding protein, has recently been recognized as a promising molecular marker of thyroid malignancy, due to its high expression in thyroid carcinomas and absence from normal or benign thyroid tissue. However, its exact role in thyroid tumor biology is still unknown. PATIENTS AND METHODS: We examined the relationship between galectin-3 and cell proliferation by comparative immunostaining for galectin-3 and proliferating cell nuclear antigen (PCNA) in paraffin-embedded tissues from 126 cases of papillary thyroid carcinoma. RESULTS: Positive cytoplasmic immunostaining for galectin-3 was found in 115 (91.3%) cases. Nuclear staining for PCNA was detectable in 93 (74.4%) cases. A low level of PCNA staining (less than 10% positive cells) was found in 36 (28.6%) cases, moderate staining for PCNA (more than 10% but less than 30% positive cells) in 35 cases (27.8%), while highly increased PCNA expression (more than 30% positive cells) was found in 32 (25.4%) cases. Moderate or strong galectin-3 expression, found in 99 cases, was associated with highly increased PCNA staining in 28.3% of them but with no detectable PCNA expression in 24.3% of them. CONCLUSION: These results suggest that overexpression of galectin-3 is not clearly related to proliferative activity of papillary thyroid carcinoma cells as assessed by PCNA immunostaining.

Biomarkers, Tumor↗

Proliferating cell nuclear antigen (PCNA) expression in pituitary adenomas: relationship to the endocrine phenotype of adenoma.

The expression of proliferating cell nuclear antigen (PCNA) correlates to cell proliferation and for this reason it is commonly considered as one of proliferation markers. Since proliferation rate is an important factor determining the tumor aggressiveness, the evaluation of PCNA index (the percentage of PCNA-immunopositive nuclei in the investigated tumor sample) is suggested as useful in predicting pituitary adenoma outcome. Seventy three unselected, surgically removed pituitary adenomas were immunostained with antibodies against the pituitary hormones or their subunits and against the proliferating cell nuclear antigen (PCNA). The highest PCNA index was found in ACTH-immunopositive tumors without the manifestation of the Cushing's disease ("silent" corticotropinomas). This value was significantly different in comparison to other adenoma subtypes including corticotropinomas manifesting themselves by Cushing's disease. The lowest PCNA index was noticed in monohormonal GH-secreting tumors. The adenomas which express more than one hormone (plurihormonal adenomas) seem to have a higher PCNA indices than monohormonal ones; the difference was significant in the case of mono- and plurihormonal prolactinomas. The recurrent tumors presented a higher mean PCNA index as compared to the primary tumors, although the difference was significant only in the case of prolactinomas. These findings suggest that the proliferative potential of pituitary adenomas is related to the tumor recurrence and hormone expression.

Adenoma↗

[Relationship between cellular DNA contents and cell proliferation of non-small cell lung cancer estimated by simultaneous quantification of PCNA and DNA contents by flow cytometer].

Cellular DNA contents and proliferating cell nuclear antigen (PCNA) expression were studied in 273 fresh specimens from 65 surgically resected non-small cell lung cancers (adenocarcinoma 36, squamous cell carcinoma 29), and the relationship between the cellular DNA contents, especially the DNA ploidy pattern, and the cell proliferation was evaluated. The cellular DNA content and PCNA labeling index (LI) % were assayed with flow cytometry using simultaneous double staining technique. The cells of G0/G1 phase of cell cycle were classified into two categories by the DNA index (DI); diploid cells (DI = 1.0) and aneuploid cells (DI > 1.0). PCNA LI % was measured at all phase and G0/G1 phase of cell cycle. PCNA LI % of diploid tumors was significantly higher than that of normal lung tissues (p < 0.05), and PCNA LI % of aneuploid tumors was significantly higher than that of diploid tumors (p < 0.05). PCNA LI % of diploid cells of tumors was significantly higher than that of diploid cells of normal lung tissues (p < 0.05), and PCNA LI % of aneuploid cells of tumors was significantly higher than that of diploid cells of tumors (p < 0.05). In adenocarcinomas, % aneuploid was directly correlated to PCNA LI % at all phase. From this result, it was concluded that DNA aneuploid tumors have a high cell proliferative pattern when the % aneuploid is high in DNA histogram.

Adenocarcinoma↗

[Proliferative activity of normal endometrial cells, endometrial hyperplasia cells and endometrial cancer cells using the monoclonal antibody to PCNA].

PCNA (Proliferating Cell Nuclear Antigen) index was studied by using an immunohistochemical technique in normal endometrium (n = 44), endometrial hyperplasia tissue (n = 12) and endometrial carcinoma (n = 60). In normal endometrial tissues, the PCNA index in the late proliferative phase (n = 11, 26.8 +/- 2.7% (mean +/- SE)) was the highest, and showed a significantly higher value than those of the early-mid secretory phase (n = 7, 12.5 +/- 3.4%, p < 0.01), late secretory phase (n = 11, 0.2 +/- 0.1%, p < 0.001), early proliferative phase (n = 7, 6.4 +/- 2.9%, p < 0.001) and postmenopausal endometrium (n = 8, p < 0.001). The mean PCNA index of premenopausal endometrial carcinoma (n = 17) was 17.1% and was not significantly higher than those of the proliferative phase and endometrial hyperplasia. Postmenopausal endometrial carcinoma (n = 43) presented a mean PCNA index of 19.9%, which was significantly higher than that of normal postmenopausal endometrium (p < 0.005). There was a clear relationship between the PCNA index and nuclear grade, cervical involvement, muscle invasion, lymph-vascular space involvement and lymphnode metastasis, respectively. There was a statistically significant difference in survival between a PCNA index of less than 25% and a PCNA index of 25% or above (p < 0.05). These results suggest that PCNA immunoreactivity in endometrial carcinoma cells may be clinically useful in predicting and/or determining the prognosis, and/or the necessity of adjuvant therapy.

Adult↗

Flow cytometric measurement of proliferating cell nuclear antigen (PCNA) in solid tumors.

PURPOSE: The importance of cell kinetic parameters for prognosis and therapeutic strategy is widely accepted in oncology. Repopulation is a major problem in radiotherapy of head and neck tumors. Various assays exist for measuring the proliferation characteristics of individual tumors. However, the existing methods have several drawbacks. MATERIALS AND METHODS: PCNA (proliferating cell nuclear antigen) is expressed in a cell cycle dependent manner. There is a DNA-bound, S-phase specific fraction and a nucleoplasmatic, extractable fraction, which is detectable in all phases except G0. We describe a method for simultaneous measurement of PCNA and DNA in solid tumors using flow cytometry. The assay was applied to three different sublines (AT1, HI, H) of the Dunning rat prostate tumor R3327 and biopsies of twelve human head and neck squamous cell carcinomas. The PCNA-assay was compared to the standard BrdUrd-assay (bromodeoxyuridine) by simultaneous measurement of PCNA and BrdUrd in the animal tumors. RESULTS: Percentages of PCNA-positive cells of 29 +/- 4% (AT1), 25 +/- 7% (HI) and 3 +/- 1% (H) were calculated for the animal tumors with good rank correlation with the BrdUrd-LI. The PCNA-indices for human tumors ranged from 5 +/- 1% up to 70 +/- 9%. CONCLUSION: The flow cytometric PCNA-assay can be applied to standard biopsy material and yields reproducible results with an intratumor variation of about 5% which is small compared to the wide range of PCNA-indices in our series. The method may enhance the pretherapeutic assessment of tumor proliferation kinetics.

Animals↗

[Study on expression of proliferating cell nuclear antigen (PCNA) in ovarian cancer].

Specimens of ovarian cancers, which were obtained through laparotomy from 17 patients who received no preoperative chemotherapy and were examined histopathologically, were immunohistologically stained with anti-PCNA antibody to examine the ability to proliferate. The percent age of stained tumor cells per 1,000 cells was used as a PCNA-labeled rate. This rate was analyzed in relation to the clinical stage/histological type and the presence or absence of lymph node metastasis. 1. Tissue specimens were stained with anti-PCNA antibody in all cases, and the PCNA-labeled rate was 49.5 +/- 13.3%. 2. There were no significant differences in PCNA-labeled rates between different histological types or between clinical stages. 3. The PCNA-labeled rates was significantly higher in cases with metastasis than in those without metastasis (p < 0.01). 4. No metastasis was detected in the cases showing a PCNA-labeled rate of 50% or below. It was indicated that this PCNA-labeled rate, which can be determined with formalin-fixed specimens, is useful for evaluating the degree of biological malignancy of ovarian cancer.

Adenocarcinoma, Clear Cell↗

Role of PCNA in differentiating between malignant mesothelioma and mesothelial hyperplasia: prognostic considerations.

We investigated the PCNA immunoreactivity in 35 specimens of malignant mesothelioma and 20 specimens of mesothelial hyperplasia in order to evaluate the usefulness of this parameter in differentiating between these two mesothelial proliferations, and to determine whether PCNA has any prognostic significance in mesotheliomas. Eleven of the 35 investigated malignant mesotheliomas displayed up to 25% of positive cells for PCNA expression. The remaining 24 specimens showed high percentages of positive cells ranging from 26% to 95%. All specimens of reactive hyperplasia had less than 25% of PCNA positive cells. The difference between malignant mesothelioma and mesothelial hyperplasia for PCNA immunoreactivity was statistically significant (p < 0.01). A positive relationship was also found between PCNA expression level and the overall survival of those affected by malignant mesothelioma (p = 0.0032). Our results suggest on important role for PCNA in differentiating diagnosis of mesothelial proliferations. It remains unclear whether PCNA expression truly correlates with the proliferation rate of the malignant mesotheliomas and with the overall survival of patients affected by this neoplasm.

Adult↗

[The dual function of the proliferating cell nuclear antigen (PCNA) in the response of human cells to UV damages].

An auxiliary protein of DNA polymerases delta and epsilon, the proliferating cell nuclear antigen (PCNA), is necessary for efficient DNA replication in vivo and in vitro, and also for the repair synthesis in vitro, but its role in the excision repair of genome in vivo is not exactly established. In S-phase of unirradiated cells, PCNA is tightly bound to focal centers of DNA replication and is not removed by treatment with detergent Triton X-100, but is completely extracted from non-S-phase cells by the indicated detergent. It was shown earlier that after UV-irradiation PCNA could not be removed by the detergent even from non-S-phase cells. It was interpreted as the evidence of PCNA integration into the repair complex and of the participation of this protein in repair synthesis in vivo. In the present work the data were obtained indicating that the role of PCNA in cell response to UV-damage was not confined only to its possible involvement in repair synthesis. With the help of confocal microscopy it was established that in Triton X-100-extracted normal cells PCNA did not colocalize with the well known excision repair protein XPB/ERCC3, defective in cells from Xeroderma pigmentosum (complementation group B) patients. XPB-protein is induced by UV-irradiation in normal cells, and this induction is not observed in repair deficient cells. However, in such cells UV-light induces a detergent-resistant form of PCNA, and this form is obviously not connected with repair. It cannot be excluded that a rapid PCNA immobilization immediately after UV-irradiation of cells is needed for the facilitation of photochemical damage bypass during the subsequent replication of genome.

Adenocarcinoma↗

[Comparison of flow-cytometry and immunohistochemistry with proliferating monoclonal antibody. Cell nuclear antigen (PCNA) in the study of proliferative kinetics of renal carcinoma].

Tumor Proliferative Fraction (TPF) has been shown to correlate with prognosis in some malignancies. A reliable, accurate method for application in a clinical practice is still being sought. The aim of this study is to compare TPF as determined by Proliferating Cell Nuclear Antigen (PCNA) and Flow Cytometry (FC) in 36 consecutive patients affected by Renal Cell Carcinoma (RCC). Proliferating cells were identified in paraffined sections using a anti-PCNA monoclonal antibody (PC 10 Dako). Cell suspension for FC were prepared from fresh/frozen samples DNA index and S phase were evaluated using a computerized program (Multicycle, Phoenix). 16 samples (47.1%) were found to be aneuploid by FC (DI range 0.72-2.40). Aneuploid vs diploid tumors had significantly higher mean FC-S phase (p = 0.049) and PCNA LI (p = 0.034). Weak correlation (r-Spearman 0.416 p = 0.01) was found between PCNA LI and grading and near to significativity between PCNA LI and tumor size (r = 0.335 p = 0.0061). When patients are classified according to nuclear grading, is evident that all PCNA G4 are aneuploid and that 62.5% of PCNA G1 are diploid. A week correlation near to significativity is found between PCNA LI and S phase only in the aneuploid tumors. A more reliable measurement of TPF in RCC could be provided by combining the two methods. Further research on larger series is needed.

Adult↗

Evaluation of proliferating cell nuclear antigen (PCNA) in supraglottic carcinoma.

It is widely accepted that tumor invasion and metastasis are the primary causes for the lethal clinical outcome of cancers. In recent years, attention has been drawn to PCNA (Proliferating Cell Nuclear Antigen) to predict the prognosis of some cancers. In the present paper, we have studied anti-PCNA antibody PC10 in supraglottic cancer by means of immunohistochemistry using paraffin-embedded sections, to demonstrate its clinical significance in this type of malignancy. Twenty-two patients with supraglottic cancer, including T1 (5 cases), T2 (13 cases) and T4 (4 cases) with N- (14 cases) and N+ (8 cases), were investigated for the PCNA expression. The percentages of PCNA positive cells were divided into three groups: < 25%, 25-75%, > 75%, with the range from 10.6 to 95.2%. Results showed that PCNA was well correlated with lymph node metastasis, and appeared to have an inverse correlation with histopathological grades. In this small group, we did not find that PCNA was correlated with T stages and tumor size. However, compared with other T-stages and tumor sizes, the correlation between lymph node metastasis and PCNA seemed to have more clinical significance in T2-stage and in tumors larger than 2 cm. PCNA could be used as a marker in predicting the clinical outcome in supraglottic cancers. An analysis on a large scale is anticipated.

Adult↗

Increase of proliferating cell nuclear antigen (PCNA) expression in HPV-18 positive oral squamous cell carcinomas.

Several studies have established a probable relationship between HPV infections and oral neoplasia. The present study analyze the importance of the integration of DNA of HPV type 18 on the proliferative capability of oral squamous cell carcinoma (OSCC) by the study of PCNA expression. Thirty seven patients with OSCC were studied. A complete clinical history and histopathological study was performed. DNA of HPV-18 was found in 7 of the 37 oral OSCCs (19.1%). PCNA expression appeared in 75.7% of OSCCs (28 cases). 9 OSCCs (24.3%) were completely negative, whereas 13 (35.1%), 8 (21.6%) and 7 (18.9%) show minimal, moderate and intense PCNA expression. 4 HPV-18 positive OSCCs showed a intense PCNA expression, 1 OSCC showed moderate PCNA expression, whereas 2 OCSSs showed minimal PCNA expression. Statistical correlations between PCNA expression and DNA HPV-18 amplification showed a more intense PCNA expression in HPV-18 positive OSCCs (p = 0.023). Further studies are needed to establish whether the increase of cellular proliferation induced by HPV-18 has prognostic consequences.

Adult↗

Prognostic significance of PCNA expression in laryngeal cancer.

OBJECTIVE: To assess the prognostic value of proliferating cell nuclear antigen (PCNA) in laryngeal carcinoma and its relation with other known prognostic clinicopathologic variables. DESIGN: A retrospective cohort study of 92 patients chosen randomly from patients treated between 1964 and 1993 with the diagnosis of laryngeal cancer. Prognostic factors including PCNA expression, grade, lymphovascular invasion, depth of tumor margins, neck metastasis, and clinical outcome were evaluated. SETTING: Hacettepe University Medical Faculty, Ankara, Turkey. PATIENTS: Eighty-five men and 7 women operated on for squamous cell carcinoma of the larynx were studied. Sixty-nine patients had total and 20 patients had partial laryngectomy with neck dissection, and 3 patients had endolaryngeal tumor excision. INTERVENTION: Hematoxylin and eosin-stained sections were reevaluated for grade, lymphovascular invasion, and depth of tumor margins; sections stained with monoclonal antibody against PC10 were examined for PCNA expression. RESULTS: The PCNA index correlated with grade, lymphovascular invasion, depth of tumor margins, neck metastasis, and local-regional recurrence. The PCNA index values of patients with occult metastasis were significantly higher than those of patients without metastasis (P=.006). CONCLUSIONS: The PCNA index is a more sensitive variable than grade in predicting tumor proliferation, occult lymph node metastasis, and prognosis. These results suggest that the PCNA index can be used in decision making for treatment and assessment of prognosis in laryngeal carcinomas.

Adult↗